<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779918</url>
  </required_header>
  <id_info>
    <org_study_id>TB.2020.01.01</org_study_id>
    <nct_id>NCT04779918</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Clinical Outcomes of Ventral Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix</brief_title>
  <acronym>BRAVO II</acronym>
  <official_title>A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tela Bio Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emergent Clinical Consulting, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tela Bio Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the post-operative complications and re-herniations&#xD;
      following the use of OviTex in subjects with ventral hernias. Up to 100 subjects will&#xD;
      participate in the study from up to 3 investigator sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to evaluate the post-operative complications and re-herniations&#xD;
      following the use of OviTex in ventral hernias being treated robotically. It is a single-arm&#xD;
      study and all subjects will receive OviTex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early surgical site occurrences or wound related events</measure>
    <time_frame>occurring within the first 3 months of the ventral hernia repair</time_frame>
    <description>Incidence of early peri- and post-operative surgical site occurrences or wound related events noted at the hernia repair site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early post-operative complications</measure>
    <time_frame>occurring within the first three months of the ventral hernia repair.</time_frame>
    <description>Incidence of other early post-operative complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late surgical site occurrences or wound related events</measure>
    <time_frame>occurring &gt; 3 months after index surgery</time_frame>
    <description>Incidence of late post-operative surgical site occurrences or wound related events noted at the hernia repair site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late post-operative complications</measure>
    <time_frame>occurring &gt; 3 months after index surgery.</time_frame>
    <description>Incidence of other late post-operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Assessed at day 30, day 90, 12 months, and 24 months post-op</time_frame>
    <description>Patient Reported Outcomes (QoL and pain assessments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hernia Recurrence</measure>
    <time_frame>at post-operative day 90 and months 12 and 24</time_frame>
    <description>True hernia recurrence at the site of surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hernia, Ventral</condition>
  <arm_group>
    <arm_group_label>OviTex Reinforced Tissue Matrix</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a single-arm study. All study subjects will receive OviTex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OviTex Reinforced Tissue Matrix</intervention_name>
    <description>All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.</description>
    <arm_group_label>OviTex Reinforced Tissue Matrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject suffers from a ventral or incisional hernia that requires surgical repair with&#xD;
             the use of an implant to reinforce or replace weakened or missing tissue.&#xD;
&#xD;
          2. The patient is scheduled for a robotic approach.&#xD;
&#xD;
          3. The size of the implant needed for repair is expected to be less than 25 x 40 cm for&#xD;
             OviTex Core and 1S and 12 x 18 cm for OviTex LPR.&#xD;
&#xD;
          4. Subject meets CDC/SSI Wound Classification Class I (Clean), Class II&#xD;
             (Clean-Contaminated) or Class III (Contaminated) criteria.&#xD;
&#xD;
          5. Subject has VHWG score of Grade 1, 2 or 3.&#xD;
&#xD;
          6. Subject is willing and able to sign an informed consent for the study and has signed&#xD;
             the IRB approved Informed Consent form for this study.&#xD;
&#xD;
          7. Subject is able to complete Quality of Life (QoL) and pain questionnaires.&#xD;
&#xD;
          8. Subject is at least 22 years old, (or considered an adult per state law).&#xD;
&#xD;
          9. Subject is able to participate fully in, and for the full duration of, the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a BMI of &gt; 40&#xD;
&#xD;
          2. Subject meets CDC/SSI Wound Classification Class IV (Dirty-Infected) criteria&#xD;
&#xD;
          3. Subject has VHWG score of Grade 4.&#xD;
&#xD;
          4. Subject is female and is pregnant.&#xD;
&#xD;
          5. Subject has a life expectancy of &lt; 2 years making it unlikely that the subject will&#xD;
             successfully achieve two-year follow-up.&#xD;
&#xD;
          6. Subject has recent history of drug or alcohol abuse (in last 3 years).&#xD;
&#xD;
          7. Subject has an allergy to ovine-derived products.&#xD;
&#xD;
          8. Subject has participated in another clinical trial within the past 30 days or is&#xD;
             currently involved in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emily Gentile</last_name>
    <phone>610-454-7200</phone>
    <email>emily@emergentclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neal Overbeck</last_name>
    <phone>484-320-2930</phone>
    <phone_ext>2958</phone_ext>
    <email>noverbeck@telabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Gentile</last_name>
      <email>emily@emergentclinical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>use of mesh</keyword>
  <keyword>robotic hernia repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

